Literature DB >> 33595871

Cardiac amyloidosis-A review of current literature for the practicing physician.

Samantha Ash1, Eran Shorer1, Devyani Ramgobin2, Maique Vo2, Jonathan Gibbons2, Reshma Golamari3, Rahul Jain4, Rohit Jain3.   

Abstract

The amyloidoses are a family of diseases in which misfolded precursor proteins aggregate to form amyloid and deposit in body tissues. A very serious yet underrecognized form of this disease is cardiac amyloidosis, in which amyloid deposits into the extracellular space of the myocardium, resulting in thickening and stiffening of ventricular walls with resultant heart failure and conductive dysfunction. This review provides a discussion of the pathogenesis and clinical presentation of cardiac amyloidosis subtypes, as well as an up-to-date approach to diagnosis and treatment. Significant progress has been made in recent years regarding diagnosis and treatment of this condition, but prognosis remains heavily reliant on early detection of the disease. Two types of precursor protein are responsible for most cardiac amyloidosis cases: transthyretin amyloid, and immunoglobulin-derived light chain amyloid. An early diagnosis of cardiac amyloidosis can allow for novel treatment modalities to be initiated with the potential to improve prognosis.
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Entities:  

Keywords:  AL; ATTR; amyloid deposits; amyloidosis; cardiac amyloidosis

Mesh:

Substances:

Year:  2021        PMID: 33595871      PMCID: PMC7943900          DOI: 10.1002/clc.23572

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   3.287


  39 in total

Review 1.  The workings of the amyloid diseases.

Authors:  Vittorio Bellotti; Mario Nuvolone; Sofia Giorgetti; Laura Obici; Giovanni Palladini; Paola Russo; Francesca Lavatelli; Vittorio Perfetti; Giampaolo Merlini
Journal:  Ann Med       Date:  2007       Impact factor: 4.709

Review 2.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

Review 3.  Cardiac amyloidosis.

Authors:  Ana Martinez-Naharro; Philip N Hawkins; Marianna Fontana
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

Review 4.  The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis.

Authors:  Filipe Penna de Carvalho; Fernanda Erthal; Clerio F Azevedo
Journal:  Magn Reson Imaging Clin N Am       Date:  2019-05-09       Impact factor: 2.266

5.  Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Authors:  Arnt V Kristen; Senda Ajroud-Driss; Isabel Conceição; Peter Gorevic; Theodoros Kyriakides; Laura Obici
Journal:  Neurodegener Dis Manag       Date:  2018-11-27

6.  Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Authors:  Giovanni Palladini; Efstathios Kastritis; Mathew S Maurer; Jeffrey Zonder; Monique C Minnema; Ashutosh D Wechalekar; Arnaud Jaccard; Hans C Lee; Naresh Bumma; Jonathan L Kaufman; Eva Medvedova; Tibor Kovacsovics; Michael Rosenzweig; Vaishali Sanchorawala; Xiang Qin; Sandra Y Vasey; Brendan M Weiss; Jessica Vermeulen; Giampaolo Merlini; Raymond L Comenzo
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

7.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

Review 8.  Cardiac amyloidosis: pathology, nomenclature, and typing.

Authors:  Joseph J Maleszewski
Journal:  Cardiovasc Pathol       Date:  2015-08-01       Impact factor: 2.185

9.  Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation.

Authors:  S Dubrey; A Pollak; M Skinner; R H Falk
Journal:  Br Heart J       Date:  1995-11

10.  Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.

Authors:  Candida Cristina Quarta; Esther Gonzalez-Lopez; Janet A Gilbertson; Nichola Botcher; Dorota Rowczenio; Aviva Petrie; Tamer Rezk; Taryn Youngstein; Shameem Mahmood; Sajitha Sachchithanantham; Helen J Lachmann; Marianna Fontana; Carol J Whelan; Ashutosh D Wechalekar; Philip N Hawkins; Julian D Gillmore
Journal:  Eur Heart J       Date:  2017-06-21       Impact factor: 29.983

View more
  9 in total

1.  Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group.

Authors:  Fernando Mut; Isabel Carvajal; Jorge Camilletti; Juan Erriest; Erick Alexanderson; Gabriel Blacher Grossman
Journal:  J Nucl Cardiol       Date:  2022-05-31       Impact factor: 3.872

Review 2.  Advanced Imaging in Cardiac Amyloidosis.

Authors:  Dominik Waldmeier; Jan Herzberg; Frank-Peter Stephan; Marcus Seemann; Nisha Arenja
Journal:  Biomedicines       Date:  2022-04-15

Review 3.  Cardiac amyloidosis-A review of current literature for the practicing physician.

Authors:  Samantha Ash; Eran Shorer; Devyani Ramgobin; Maique Vo; Jonathan Gibbons; Reshma Golamari; Rahul Jain; Rohit Jain
Journal:  Clin Cardiol       Date:  2021-02-17       Impact factor: 3.287

Review 4.  Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.

Authors:  Katrine Bay; Finn Gustafsson; Michael Maiborg; Anne Bagger-Bahnsen; Anne Mette Strand; Trine Pilgaard; Steen Hvitfeldt Poulsen
Journal:  ESC Heart Fail       Date:  2022-03-27

Review 5.  Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options.

Authors:  Begum Yetis Sayin; Ali Oto
Journal:  Cardiol Ther       Date:  2022-03-30

Review 6.  Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.

Authors:  Weiqin Lin; Pairoj Chattranukulchai; Alex Pw Lee; Yen-Hung Lin; Wen-Chung Yu; Houng-Bang Liew; Abraham Oomman
Journal:  Clin Cardiol       Date:  2022-07-06       Impact factor: 3.287

7.  Cardiac Amyloidosis-Challenging Diagnosis and Unclear Clinical Picture.

Authors:  Sylwia Kozak; Krzysztof Ulbrich; Maciej Migacz; Krzysztof Szydło; Katarzyna Mizia-Stec; Michał Holecki
Journal:  Medicina (Kaunas)       Date:  2021-05-06       Impact factor: 2.430

8.  Cardiac Amyloidosis with Discordant QRS Voltage between Frontal and Precordial Leads.

Authors:  Csilla-Andrea Eötvös; Roxana-Daiana Lazar; Iulia-Georgiana Zehan; Erna-Brigitta Lévay-Hail; Giorgia Pastiu; Mihaela Pop; Anca Simona Bojan; Sorin Pop; Dan Blendea
Journal:  Medicina (Kaunas)       Date:  2021-06-27       Impact factor: 2.430

9.  Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis.

Authors:  Darae Kim; Jin-Oh Choi; Kihyun Kim; Seok Jin Kim; Jung-Sun Kim; Eun-Seok Jeon
Journal:  ESC Heart Fail       Date:  2021-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.